Cash on hand, page-2

First with regards to P3 enrollment:
From the Annual Report 2020/2021:
"Over an approximate 18‑month period, both trials will each enroll approximately 990 patients."

18 months enrollment from start Mar 2021 => Full enrollment Sep 2022
12 months follow-up from Sep 2022 => read-out 4Q CY 2023 rather than official wording "of reporting Phase 3 topline data in 2H CY 2023"

Second with regards to funding:
From the Half-Year Report Dec 2020:
"The proceeds of the financing will primarily be used to progress OPT-302 into the Phase 3 clinical program."
=> "into" unequal to "through"

From the Annual Report 2020/2021:
"The proceeds will primarily be used to progress OPT‑302 in pivotal Phase 3 registration trials."
=> again "in" unequal to "through"

I doubt existing cash will last through YE 2023 at current burn rate of approx. AUD 45 MN / USD 30 MN per half year. A CR before P3 topline data seems hardly evitable.
Any thoughts? @whytee? Others?